Biotech Values

[iwfal]

but the lawsuit’s NPV for MNTA is greatly reduced with a settlement presumably off the table.

Just to be clear, I think the NPV is lower because, as I have noted before, I think it is going to be tough to get the cash out of WPI/A*. NOT because I think that the shift to royalty arrangement killed MNTAs claim on settlement. I'd be very surprised if MNTA hadn't had repeated discussions/agreements with NVS that in making a tough settlement proposal to A* MNTA was running a greater risk than NVS and would be owed more in the event that WPI rejected it.